Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX15/2503 With or Without Ipilimumab or Nivolumab in Head and Neck Cancer
NCT03690986Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Nov 2018
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pepinemab in head and neck squamous cell carcinoma (HNSCC) (6 arms), sponsored by Emory University. Primary endpoints: Change in immune profile in the tumor microenvironment, Change in circulating percentage of immune suppressor subsets in peripheral blood and 1 more. Started Nov 2018; status: active, not recruiting.
02
Drugs
pepinemab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03690986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690986.